Israel's Teva Pharmaceutical Industries has posted another strong set of financials for the second quarter, with net income rising 5% to $539 million, or $0.65 per share (+3%).

Sales rose 18% to $2.82 billion, helped by sales of Teva’s generic versions of GlaxoSmithKline’s antidepressant Wellbutrin XL (extended-release bupropion) and Johnson & Johnson’s antipsychotic Risperdal (risperidone), launched during the quarter. The firm’s copycat versions of Wyeth’s gastrointestinal drug Protonix (pantoprazole), Novartis’ blood-pressure-lowering treatment Lotrel (almodipine/benazepril) and Merck & Co’s osteoporosis medicine Fosamax (alendronate) also performed well.

Teva noted that as of July 23, it had 149 product applications awaiting final US Food and Drug Administration approval. The company believes it will be the first to file on 50 of these, relating to products whose annual US branded sales are worth $39 billion. In Europe, Teva has 220 compounds pending submission in 454 formulations.

The company’s branded business was again dominated by Copaxone (glatiramer acetate). The multiple sclerosis treatment brought in $563 million, an increase of 29%, helped by strong growth outside the USA ($231 million; +53%). Sales of Azilect (rasagiline), the subject of a recent promising study which highlighted the drug’s efficacy in slowing the progression of Parkinson’s disease, reached $42 million, up 50%. Global respiratory revenues were $168 million, down 7% decrease on the corresponding quarter last year, reflecting a decline in demand for the firm's asthma inhaler ProAir (albuterol).

Chief executive Shlomo Yanai said he was pleased with another solid quarter and noted that “these are exciting times for Teva”, following the signing of its agreement to acquire the USA’s Barr Pharmaceuticals. He said that the deal will “dramatically increase the scale and scope of Teva’s leadership, allow us to exceed our strategic targets and create great value for all of our stakeholders.”